ESR1 and breast cancer: In contrast to normal breast, ER+ proliferating cells are common in luminal tumors and their proliferation is inhibited by ER-antagonists1–4, suggesting that the development of ER+ human breast cancer is associated with dysregulation of ER and proliferation.